Standard Operating Procedure for Escalation of Critical Questions From Health Authorities
| Department | Regulatory Affairs |
| SOP No. | RA/2026/728 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 14/04/2026 |
| Effective Date | 14/04/2026 |
| Review Date | 14/04/2028 |
Purpose
This SOP defines the standardized and controlled procedure to promptly identify, evaluate, and escalate critical questions received from health authorities during regulatory submissions or inspections. It aims to ensure timely response, maintain regulatory compliance, and support effective communication with health authorities, thereby minimizing risks to product approval timelines and maintaining the integrity of the regulatory process.
Scope
This procedure applies to all regulatory affairs personnel and associated functional areas involved in handling health authority queries across all product types, dosage forms, and submission categories within the organization. It covers the receipt, initial assessment, internal coordination, escalation, and documentation of critical questions arising from health authority deficiency letters, information requests, or inspection reports. Routine or non-critical queries that do not impact regulatory decisions or timelines are excluded from this SOP.
Responsibilities
- Regulatory Affairs Executive: Receives and logs health authority queries, performs initial evaluation to identify critical questions.
- Regulatory Affairs Manager: Reviews initial assessment, determines escalation necessity, facilitates cross-functional coordination.
- Subject Matter Experts (SMEs): Provide technical input, impact assessment, and propose responses.
- Quality Assurance: Reviews critical questions and responses for GMP and compliance impact.
- Document Control: Maintains records of all communications and related documentation.
- Regulatory Affairs Director: Oversees escalation process and final approval of response strategies.
Accountability
The Regulatory Affairs Director is accountable for ensuring effective implementation, adherence, periodic review, continuous improvement, and compliance with this SOP. The Director is responsible for escalating critical issues to senior management and regulatory authorities as required and ensuring adequate training and resource allocation to support this process.
Procedure
1. Receipt and Logging: Upon receipt of a health authority communication, the Regulatory Affairs Executive shall log the document in the Health Authority Queries Log within one working day, noting receipt date, reference number, and sender details.
2. Initial Evaluation: The Regulatory Affairs Executive shall perform a preliminary review to identify critical questions, defined as queries that could impact regulatory approvals, product quality, safety, or compliance status. Queries deemed critical must be flagged and escalated immediately.
3. Notification and Escalation: Critical questions shall be immediately escalated to the Regulatory Affairs Manager who will notify relevant internal stakeholders, including SMEs, Quality Assurance, and Document Control teams. An escalation meeting shall be scheduled within two working days to discuss the query.
4. Cross-Functional Assessment: SMEs shall conduct detailed impact assessments concerning product, process, quality, and compliance parameters. Inputs shall be compiled into an assessment report outlining potential regulatory, technical, and business risks.
5. Response Development: Based on the assessment, a draft response shall be developed collaboratively by Regulatory Affairs, SMEs, and Quality Assurance ensuring technical accuracy, compliance adherence, and alignment with regulatory expectations.
6. Review and Approval: The draft response and assessment report shall be reviewed by the Regulatory Affairs Manager and Quality Assurance for completeness and compliance, followed by the Regulatory Affairs Director for final approval.
7. Submission: Approved responses shall be formally submitted to the health authority within stipulated timelines, ensuring all communications are archived.
8. Documentation and Record Keeping: All correspondence, logs, assessment reports, meeting minutes, approvals, and submission evidence shall be maintained in the Health Authority Queries File according to document retention policies.
9. Follow-up and Closure: Post-submission, Regulatory Affairs shall monitor health authority feedback and update the query log status. Queries shall be formally closed only after confirmation of satisfactory resolution.
10. Periodic Review: The Regulatory Affairs Director shall ensure periodic review of the escalation process effectiveness, analyze trends in critical questions, and implement corrective actions or training as needed.
This procedure must adhere to applicable Good Manufacturing Practices (GMP), internal quality policies, and maintain confidentiality of regulatory communications at all times.
Abbreviations
- GMP: Good Manufacturing Practices
- RA: Regulatory Affairs
- SME: Subject Matter Expert
- QA: Quality Assurance
- HA: Health Authority
- Log: Register or record of entries
Documents
The following documents are required and referenced in this SOP:
- Health Authority Queries Log (Annexure-1)
- Critical Question Impact Assessment Report Template (Annexure-2)
- Regulatory Response Approval Form (Annexure-3)
References
- ICH Q7 Good Manufacturing Practice Guide
- FDA Guidelines for Responding to Regulatory Queries
- EU GMP Annex 16 – Certification by a Qualified Person and Batch Release
- Internal Quality Management System Policy Documents
- Company Document Control Procedures
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Health Authority Queries Log
Purpose: To systematically record and track all health authority queries including receipt, evaluation, escalation, and closure details.
| Query ID | Date Received | Health Authority | Reference Number | Subject | Critical (Y/N) | Assigned To | Status | Closure Date |
|---|---|---|---|---|---|---|---|---|
| HAQ-2026-001 | 10/04/2026 | FDA | FDA-2026-PR-045 | Stability Data Clarification | Y | Regulatory Affairs Manager | In Progress | |
| HAQ-2026-002 | 12/04/2026 | EMA | EMA-2026-CT-078 | Manufacturing Site Change Details | N | Regulatory Affairs Executive | Closed | 13/04/2026 |
Annexure-2: Critical Question Impact Assessment Report Template
Purpose: To document the detailed evaluation and impact assessment of critical questions raised by health authorities.
| Query ID: | HAQ-2026-001 |
| Date of Assessment: | 11/04/2026 |
| Assessed By (SME): | Quality Assurance Team |
| Summary of Critical Question: | Request for additional stability data on finished product batches. |
| Impact on Product Quality: | Moderate; additional testing required to confirm shelf life. |
| Impact on Regulatory Approval: | May delay final approval by up to 30 days. |
| Risk Assessment: | Low risk to patient safety; primarily compliance and timeline risk. |
| Recommended Action: | Gather supplementary stability data, prepare detailed response. |
| Additional Comments: | Coordinate with R&D for expedited testing. |
Annexure-3: Regulatory Response Approval Form
Purpose: To document review, approval, and authorization of responses prepared for critical health authority questions.
| Query ID: | HAQ-2026-001 |
| Response Prepared By: | Regulatory Affairs Executive |
| Date Prepared: | 13/04/2026 |
| Reviewed By (QA): | Quality Assurance Manager |
| Date Reviewed: | 14/04/2026 |
| Approved By (RA Director): | |
| Date Approved: | |
| Comments: | Response is complete and compliant with regulatory standards. |
| Signature: | _________________________ |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 14/04/2026 | 1.0 | Initial issue | New SOP creation |